Stockscreener 앱 받기
9.86
2.95%
-0.30
시간 외 거래:
10.00
0.14
+1.42%
전일 마감가:
$10.16
열려 있는:
$10
하루 거래량:
244.89K
Relative Volume:
0.55
시가총액:
$304.94M
수익:
$72.35M
순이익/손실:
$-45.34M
주가수익비율:
-6.2783
EPS:
-1.5705
순현금흐름:
$-32.43M
1주 성능:
-9.87%
1개월 성능:
+29.74%
6개월 성능:
+101.22%
1년 성능:
+136.45%
1일 변동 폭
$9.80
$10.34
1주일 범위
$9.80
$11.39
52주 변동 폭
$3.22
$11.39
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
9.86 | 314.22M | 72.35M | -45.34M | -32.43M | -1.5705 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Northland Capital | Outperform |
| 2025-11-20 | 업그레이드 | BTIG Research | Sell → Neutral |
| 2025-08-08 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
Avita Medical Issues 25,213 Unquoted Options Expiring August 2036 Under Employee Incentive Scheme - Kalkine
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us
RCEL stock gains on fresh price data while Avita Medical readies next steps - ad-hoc-news.de
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
Net current asset value per share of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - Yahoo Finance
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id
Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id
AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus
AVITA Medical Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet
AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat
RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet
RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet
RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript - AOL.com
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.29%
0.75%
자본화:
|
볼륨(24시간):